Chief Scientific Officer
Education: Ph.D. in Molecular and Cellular Biology.
Background: With a master’s degree and Ph.D. in Molecular and Cellular Biology, Jan Stenvang has specialized in translational cancer research particularly focusing on drug resistance and biomarker identification.
Jan Stenvang led the initial research and discoveries upon which Scandion is based and is a co-founder of the company. Before co-founding Scandion, he spent most of his career in academia as e.g. Group Leader and Associate Professor at Copenhagen University and also as Group Leader at the biotech company Santaris Pharma. Combined, Jan Stenvang has more than 20 years of experience in cancer research.
Other ongoing assignments: None.
Scandion Oncology shares and warrants:
1,351,519 shares and 80,000 warrants.
Year of commencement of the position: 2023.
Independence: Independent in relation to both the Company and larger shareholders.